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Setting Priorities in Global Child Health Research Investments: Guidelines 
for Implementation of CHNRI Method
This article provides detailed guidelines for the implementation 
of systematic method for setting priorities in health research in-
vestments that was recently developed by Child Health and Nu-
trition Research Initiative (CHNRI). The target audience for the 
proposed method are international agencies, large research fund-
ing donors, and national governments and policy-makers. The 
process has the following steps: (i) selecting the managers of the 
process; (ii) specifying the context and risk management prefer-
ences; (iii) discussing criteria for setting health research priori-
ties; (iv) choosing a limited set of the most useful and important 
criteria; (v) developing means to assess the likelihood that pro-
posed health research options will satisfy the selected criteria; (vi) 
systematic listing of a large number of proposed health research 
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Proposals for health research funding are far 
exceeding available resources. Increasingly, 
there is a need to set priorities in health re-
search investments in a fair, transparent, and 
systematic way. In 2005, Child Health and 
Nutrition Research Initiative (CHNRI, www.
chnri.org), an initiative of the Global Forum 
for Health Research, launched a project to de-
velop a systematic method for setting priori-
ties in health research investments and to ap-
ply it to global child health (1). This effort was 
motivated by a notion that current research 
investment prioritization approaches suffer 
from many shortcomings which may partly be 
responsible for persisting high levels of mortal-
ity in children globally (2-4). The target audi-
ence for the proposed method are internation-
al agencies, large research funding donors, and 
national governments and policy-makers. The 
CHNRI method is a flexible process that en-
ables prioritizing health research investments 
at any level: institutional, regional, national, 
international, or global.
Selecting managers of the process
CHNRI method is a process managed by a 
relatively small team of persons. This team 
needs to appropriately represent investors in 
health research, their interests, and visions. 
Like any other investing, health research fund-
ing is associated with possible gains and prof-
its, but also risks and losses. The key concept 
of CHNRI’s methodology is that all health re-
search should have a common ultimate goal, 
which is to reduce existing burden of disease 
and disability and improve health. Future re-
ductions in the existing disease burden that 
will result from supported health research 
are considered “profits.” However, because 
of many uncertainties inherent to health re-
search, many investments will never sufficient-
ly contribute to reduction in disease burden to 
justify the investments.
The purpose of the CHNRI priority set-
ting method is to inform the investors in 
health research about the risks associated with 
their investments. Each research investment 
option needs to be judged according to a set 
of criteria. Those criteria will assess likelihood 
that proposed research option could realisti-
cally contribute to disease burden reduction 
within the context in which investments are 
taking place (4).
Specifying context and risk management 
preferences
Priority setting in health research investments 
is not an abstract, theoretical exercise with 
a single possible correct outcome, such as a 
mathematical problem. It is a process that oc-
curs within complex circumstances of the real 
world. The decisions will, therefore, strongly 
depend on the context in which the process 
takes place and on risk preferences of the in-
vestors.
At this point, a small group of process 
managers (who represent the investors) needs 
to specify the context and their risk preferenc-
es. The context is specified by thoroughly dis-
cussing and carefully defining the following: 
(i) context in space; (ii) disease, disability, and 
death burden; (iii) context in time; (iv) stake-
options; (vii) pre-scoring check of all competing health research options; (viii) scoring of health research options using 
the chosen set of criteria; (ix) calculating intermediate scores for each health research option; (x) obtaining further 
input from the stakeholders; (xi) adjusting intermediate scores taking into account the values of stakeholders; (xii) 
calculating overall priority scores and assigning ranks; (xiii) performing an analysis of agreement between the scorers; 
(xiv) linking computed research priority scores with investment decisions; (xv) feedback and revision. The CHNRI 
method is a flexible process that enables prioritizing health research investments at any level: institutional, regional, 
national, international, or global.
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holders; and (v) risk management preferences. 
Box 1 provides guidelines on how this should 
be done.
Discussing criteria for setting health 
research priorities
There is a large number of nearly indepen-
dent criteria that can be used to discriminate 
between any two competing “health research 
investment options,” giving one of them pref-
erence over the other. The central challenge 
is that the decisions on investment priorities 
based on different criteria will necessarily con-
flict each other. This means that, when choos-
ing between any two proposed research op-
tions, some criteria will give preference to one 
of them, while other will prefer the other.
At this point, managers of the priority set-
ting process should try to list possible crite-
ria appropriate to their specific context. Box 
2 provides a list of criteria that can serve as an 
example and starting point. There is no real 
limit to a number of priority setting criteria 
that may seem appropriate to different con-
texts. However, with inclusion of more crite-
ria to the list, they will begin to overlap with 
the already listed ones, so their potential use-
fulness as independent criteria will soon begin 
to decrease.
Choosing a limited set of the most useful 
and important criteria
In this step, managers of priority setting pro-
cess need to select a set of priority setting cri-
teria from the longer list that should be suffi-
ciently informative to discriminate between 
the competing research options. Figure 1 
shows an example of how this can be done. 
Competing research options are expected to 
initially generate new knowledge, which then 
needs to be translated into health interven-
tion. This translation may either lead to im-
provement of an existing intervention, or de-
Box 1. Guidelines on defining the context in which research priorities will be set
(i) Context in space: What is the population in which the investments in health research should contribute to disease burden 
reduction and improved health? (eg, all developing countries/all children under 5 years of age/people exposed to a specific 
risk factor);
(ii) Disease, disability, and death burden: What is known about the burden of disease, disability, and death that will be addressed 
by supported health research? Can it be measured and quantified (eg, in disability-adjusted life years – DALYs – or in some 
other way)?
(iii) Context in time: In how many years are the first results expected (in terms of reaching the endpoints of health research, 
translating and implementing them, which is then expected to achieve detectable disease burden reduction)?
(iv) Stakeholders: Who are the main groups in the society whose values and interests should be respected in setting health 
research investment priorities?
(v) Risk management preferences: What will be investment strategy in health research with respect to risk preferences? Will all 
the funding support a single (or a few) expensive high-risk high-profit research options (eg, vaccine development), or will the 
risk be balanced and diversified between many research options which will have different levels of “risks” and “profits” 
associated with them?
Figure 1. A simple framework developed by Child Health and Nutri-
tion Research Initiative, which identifies some of the apparent criteria 
that can be used for setting priorities between the proposed health 
research options.
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velopment of a new one. The implementation 
of that intervention will eventually reduce dis-
ease burden, which is the ultimate aim of any 
health research investment (Figure 1).
The criteria that assess the likelihood of the 
progress through this simple framework are: 
(i) answerability, (ii) effectiveness, (iii) deliv-
erability, (iv) maximum potential for disease 
burden reduction, and (v) the effect on equity. 
CHNRI recommends these five criteria to be 
used in almost all contexts. Some of them may 
even be merged – eg, “effectiveness” and “de-
liverability” criteria could be merged in some 
contexts into a more general criterion called 
“usefulness.” Also, “maximum potential for 
disease burden reduction” and “effect on equi-
ty” criteria can be merged into a more general 
criterion called “impact.”
Additional criteria (those shown in Box 2, 
or any other useful criteria) may be added to 
these ones suggested here, if the management 
team decides that they are important with-
in their context. It is entirely up to the team 
of process managers to decide on the final list 
of criteria that will be useful for their partic-
ular exercise in priority setting in health re-
search investments. Examples on how this was 
achieved in practice can be found in some pub-
lished examples of implementation (5,6)
Developing means to assess the likelihood 
that proposed health research options will 
satisfy selected criteria
After the managers selected the criteria, they 
should invite a group of technical experts. The 
experts should take the process through the 
next three steps (listing, checking, and scor-
ing research options), working closely with the 
management team.
The first task for technical experts is to de-
velop a set of three simple questions that will 
Box 2. Examples of the possible criteria which can be used for setting priorities in health research investments
• Answerability? (some health research options will be more likely to be answerable than the others)
• Attractiveness? (some health research options will be more likely to lead to publications in high-impact journals)
• Novelty? (some health research options will be more likely to generate truly novel and non-existing knowledge)
• Potential for translation? (some health research options will be more likely to generate knowledge that will be translated into health 
intervention)
• Effectiveness? (some health research options will be more likely to generate/improve truly effective health interventions)
• Affordability? (the translation or implementation of knowledge generated through some health research options will not be afford-
able within the context)
• Deliverability? (some health research options will lead to/impact health interventions that will not be deliverable within the context)
• Sustainability? (some health research options will lead to/impact health interventions that will not be sustainable within the con-
text)
• Public opinion? (some health research options will seem more justified and acceptable to general public than the others)
• Ethical aspects? (some health research options will be more likely to raise ethical concerns than the others)
• Maximum potential impact on burden? (some health research options will have a theoretical potential to reduce much larger portions 
of the existing disease burden than the others)
• Equity? (some health research options will lead to health interventions that will only be accessible to the privileged in the society/
context, thus increasing inequity)
• Community involvement? (some health research options will have more additional positive side-effects through community involve-
ment)
• Cost and feasibility? (all other criteria being equal, some research options will still require more funding than the others and thus 
be less feasible investments)
• Likelihood of generating patents/lucrative products? (some research options will have greater likelihood of generating patents or 
other potentially lucrative products, thus promising greater financial return on investments, regardless of their impact on disease 
burden)
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address each of the selected criteria. These ques-
tions should jointly help to assess the likeli-
hood that proposed research options will satis-
fy the selected criteria. It is recommended that 
the questions should be simple, sufficiently in-
formative, easily understandable, and answer-
able simply as “yes” or “no.” Box 3 shows an ex-
ample of how the questions were developed in 
some of the conducted exercises to address the 
set of 5 criteria: answerability, effectiveness, de-
liverability, maximum potential for disease bur-
den reduction, and the effect on equity (5,6).
Systematic listing of a large number of 
proposed health research options
Research priorities will usually be set under 
two types of circumstances. In the first scenar-
io, a funding agency/government will aim to 
distribute its annual budget in the most ratio-
Box 3. Example of yes/no questions that can be used to assess likelihood whether proposed health research options 
satisfy the chosen priority-setting criteria
CRITERION 1: ANSWERABILITY
1. Would you say the research question is well framed and endpoints are well defined?
2. Based on: (i) the level of existing research capacity in proposed research and (ii) the size of the gap from current level of knowledge 
to the proposed endpoints; would you say that a study can be designed to answer the research question and to reach the proposed 
endpoints of the research?
3. Do you think that a study needed to answer the proposed research question would obtain ethical approval without major con-
cerns?
CRITERION 2: EFFECTIVENESS
1. Based on the best existing evidence and knowledge, would the intervention which would be developed/improved through proposed 
research be efficacious?
2. Based on the best existing evidence and knowledge, would the intervention which would be developed/improved through proposed 
research be effective?
3. If the answers to either of the previous two questions are positive, would you say that the evidence upon which these opinions are 
based is of high quality?
CRITERION 3: DELIVERABILITY
1. Taking into account the level of difficulty with intervention delivery from the perspective of the intervention itself (eg, design, stan-
dardizability, safety), the infrastructure required (eg, human resources, health facilities, communication and transport infrastructure) 
and users of the intervention (eg, need for change of attitudes or beliefs, supervision, existing demand), would you say that the 
endpoints of the research would be deliverable within the context of interest?
2. Taking into account the resources available to implement the intervention, would you say that the endpoints of the research would 
be affordable within the context of interest?
3. Taking into account government capacity and partnership requirements (eg, adequacy of government regulation, monitoring and 
enforcement; governmental intersectoral coordination, partnership with civil society and external donor agencies; favorable politi-
cal climate to achieve high coverage), would you say that the endpoints of the research would be sustainable within the context of 
interest?
CRITERION 4: MAXIMUM POTENTIAL FOR DISEASE BURDEN REDUCTION
1. Taking into account the results of conducted intervention trials or for the new interventions the proportion of avertable burden 
under an ideal scenario, would you say that the successful reaching of research endpoints would have a capacity to remove 5% of 
disease burden or more?
2. To remove 10% of disease burden or more?
3. To remove 15% of disease burden or more?
CRITERION 5: EFFECT ON EQUITY
1. Would you say that the present distribution of the disease burden affects mainly the underprivileged in the population?
2. Would you say that the underprivileged would be the most likely to benefit from the results of the proposed research after its 
implementation?
3. Would you say that the proposed research has the overall potential to improve equity in disease burden distribution in the long 
term (eg, 10 years)?
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nal way, without having already received any 
specific funding proposals. It will need to de-
fine its funding priorities and launch the calls 
for research proposals, while deciding in ad-
vance how much funding will be made avail-
able for each call.
In the second scenario, an existing source 
of funding (such as a donor agency or a nation-
al ministry) will receive demands for research 
support from many research groups. The sum 
of their demands will greatly exceed the avail-
able funds.
In both scenarios, it is useful to system-
atically list (or categorize) all the compet-
ing research options. In the first scenario, this 
systematic list will ensure that all apparent re-
search options are given a fair chance to com-
pete against each other. In the second scenario, 
the systematic categorization will expose ave-
nues of research in which there is fierce com-
petition and those in which there seems to be 
no research capacity or research interest.
The number of possible health research 
options is endless and limited only by imag-
ination of all living researchers. Theoretical 
framework that enables systematic listing of 
such an endless spectrum of options is rather 
complex (1,4). However, the CHNRI meth-
odology developed a process of systematic list-
ing of all competing research options that re-
spects that theoretical framework, but is also 
practical and intuitive. In both scenarios, the 
way we propose that all competing health re-
search options should be listed (or categorized, 
if they have already been proposed for fund-
ing) is shown in a Table 1.
There is different “depth” of health re-
search. The most fundamental categorization 
of all health research is shown in the first col-
umn, which we call “research domains.” There 
are three main domains: (i) health research to 
assess burden of health problem (disease) and 
its determinants; (ii) health research to im-
prove performance of existing capacities to re-
duce the burden; and (iii) health research to 
develop new capacities to reduce the burden. 
All imaginable health research options should 
fall under one of those “domains.”
The next level of “depth” are broad “re-
search avenues,” shown in the second column. 
Within each of those avenues, large number of 
“research options” can be envisaged (the third 
column). In practice, prioritization in health 
research investments will usually be made be-
tween the competing “research options,” as 
they correspond to 3-5-year research projects. 
That is a concept that both investors and re-
searchers are familiar with and the level at 
which investment prioritization is already tak-
ing place (competition for research grants).
Table 1. Framework developed by Child Health and Nutrition Research Initiative that enables systematic listing of a very large number 
of proposed research options and research questions.
Research domain Research avenue Research option Research question
Health research to assess burden 
of health problem (disease) and its 
determinants
Measuring the burden Many “research 
options” within each 
of the avenues; 
“research options” 
should correspond 
to the level of 
3-to-5-y research 
programs
Several very specific 
“research questions” 
within each of the 
“research avenues” 
should correspond to 
the title of individual 
research papers
Understanding risk factors (in terms of their relative risks)
Measuring prevalence of exposure to risk factors
Evaluating the efficacy and effectiveness of interventions in place
Measuring prevalence of coverage of interventions in place
Health research to improve 
performance of existing capacities to 
reduce the burden
Health policy analysis
Health system structure analysis
Financing/costs analysis
Human resources
Provision/infrastructure
Operations research
Responsiveness/recipients
Improving existing interventions (their affordability, deliverability)
Health research to develop new 
capacities to reduce the burden
Basic, clinical, and public health research to advance on existing 
knowledge to develop new capacities
Basic, clinical, and public health research to explore entirely novel ideas to 
develop new capacities
Croat Med J 2008;49:720-733
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Finally, there is an even more specific lev-
el of “depth” of health research, which we call 
“research questions.” Each “research option” 
will propose to answer a number of “research 
questions.” These are very specific lines of re-
search that correspond to a title of a single re-
search article, which is another concept the re-
searchers are familiar with.
In some instances, eg, when the process is 
conducted as a mainly theoretical exercise to 
identify the most important specific questions 
that should be investigated within a given con-
text, the prioritization using CHNRI method-
ology can be performed between the compet-
ing research questions.
Table 1 is an example of how research op-
tions (or questions) should be categorized be-
fore they are scored against the relevant crite-
ria in order to be prioritized for investments. It 
should also be stressed that this step is not real-
ly necessary to identify priorities and can even 
be skipped, but it has an advantage of ensuring 
that the process is systematic, that it gives a fair 
chance to all types of health research, and that 
it exposes areas of fierce competitiveness and 
also of low interest and capacity.
Pre-scoring check of all competing health 
research options
Once that all competing research options have 
been systematically listed, technical experts 
should read them all again very carefully be-
fore the scoring. The experts need to ensure 
that scoring of all proposed research options 
against all proposed criteria should be possi-
ble. If problems are envisaged, research options 
should be reworded to enable their structured 
scoring by the experts.
The easiest way to do this is by keeping in 
mind the simple framework shown in Figure 
1. The research options (or questions) must al-
ways suggest what is the new knowledge that 
they intend to generate. Also, it should be pos-
sible to envisage an uninterrupted link be-
tween this knowledge and its proposed effect 
on disease burden reduction through transla-
tion and implementation.
Scoring of health research options using 
the chosen set of criteria
At this stage, technical experts are expected to 
use their knowledge and experience to system-
atically score research options against the cri-
teria chosen by process managers. The more 
experts agree to participate in the scoring, the 
more reliable is the outcome of the process. 
The experts should score all research options 
independently of each other. Each technical 
expert scores each research option by answer-
ing three questions per each criterion about 
that particular option. The answers to each 
question are simply:
– “I agree” (1 point), or
– “I disagree” (0 points).
There will be cases in which technical ex-
perts will not feel informed enough to answer 
some questions. In all such cases, they should 
leave those answers blank (no answer). Fur-
thermore, when technical experts are sufficient-
ly informed to answer the question, but can 
neither agree nor disagree, they are allowed to 
enter a score of 0.5 (half a point). In this way, 
such choice is distinguished from “no answer.”
When finished with scoring, each techni-
cal expert should submit his/her own scores to 
the process management team independently 
from other experts. This will ensure that the 
overall scores represent a measure of their col-
lective optimism toward each of the scored re-
search options.
Calculating intermediate scores for each 
health research option
Each research option will first achieve its in-
termediate scores. The number of intermedi-
Rudan et al: Priority Setting for Child Health Research
727
ate scores equals the number of selected crite-
ria, as each intermediate score informs process 
managers on likelihood that the research op-
tion would satisfy a specific criterion (eg, an-
swerability, effectiveness, equity, etc.). Once 
all the scores from all technical experts are 
submitted to process managers, intermediate 
scores for each criterion can be easily comput-
ed. Table 2 presents how this should be done. 
In this simple example, 12 competing research 
options (options 1-12) are being scored, only 
one criterion is used (criterion 1), research op-
tions are assessed by three scoring technical ex-
perts (TE1-3) based on three related questions 
(question 1-3). In reality, there will be more 
research options, criteria, and scoring techni-
cal experts, but all the principles of calculating 
the intermediate scores will remain exactly the 
same as shown in Table 2.
The intermediate scores are computed by 
adding up all the informed (ie, non-blank) an-
swers (“1,” “0,” or “0.5”). The achieved sum is 
then divided by the number of received in-
formed answers. Blanks are left out of the cal-
culation in both numerator and denominator. 
All intermediate scores for all research options 
will, therefore, be assigned a value between 0 
and 100%. In this way, the methodology deals 
with missing answers because it should not be 
expected that all technical experts would be suf-
ficiently informed on each possible research op-
tion to score it against each possible criterion.
In the hypothetical case shown in Table 2, 
the values for intermediate score 1 (for crite-
rion 1) ranged from 31% (option 11) to 78% 
(option 4). These figures now represent a mea-
sure of collective optimism among technical 
experts toward the likelihood that each of the 
proposed research options would satisfy the 
priority-setting criterion 1. They can now be 
prioritized and ranked according to this crite-
rion based on the scores they received. Some 
of the expected advantages of this approach in 
comparison with other priority-setting meth-
odologies are its transparency, limitation of 
personal biases through a structured survey, a 
systematic process with very specific outcomes 
and intuitive quantitative scores (3,4). The 
concerns over subjectivity of this approach are 
discussed in the concluding paragraph, where 
possible biases and limitations of the method-
ology are addressed.
Obtaining further input from stakeholders
One of the biggest challenges in prioritizing 
health research investments is involving rel-
evant stakeholders and the wider community 
in the process (7). The term “stakeholders” re-
fers to all individuals and/or groups who have 
interest in prioritization of health research in-
vestments. Stakeholders will therefore com-
prise a large and very heterogeneous group. 
Examples of stakeholders include research 
Table 2. An example of scoring of 12 hypothetical proposed research options by 3 technical experts (TE1-TE3) using a single criterion 
and computation or intermediate score for that criterion.
Criterion 1
Question 1 Question 2 Question 3
TE1 TE2 TE3 TE1 TE2 TE3 TE1 TE2 TE3 Calculation Criterion score
Option 1 1 1 0 1 1 0 1 1 — Sum (6)/answers (8) 6/8 = 0.75
Option 2 0 0.5 1 0.5 — 1 1 1 1 sum (6)/answers (8) 6/8 = 0.75
Option 3 0 — 1 0.5 0 0 1 1 — sum (3.5)/answers (7) 3.5/7 = 0.50
Option 4 0.5 1 0 1 0.5 1 1 1 1 sum (7)/answers (9) 7/9 = 0.78
Option 5 1 1 0 0 0 0.5 1 1 1 sum (5.5)/answers (9) 5.5/9 = 0.61
Option 6 1 0 0 0 0.5 0 0 1 1 sum (3.5)/answers (9) 3.5/9 = 0.39
Option 7 1 0.5 1 0 0 1 1 1 1 sum (6.5) /answers (9) 6.5/9 = 0.72
Option 8 1 0.5 1 0 0 0 1 1 1 sum (5.5)/answers (9) 5.5/9 = 0.61
Option 9 1 0 1 0 — 0.5 0 1 1 sum (4.5)/answers (8) 4.5/8 = 0.56
Option 10 0 1 1 0 — 1 1 0.5 1 sum (5.5)/answers (8) 5.5/8 = 0.69
Option 11 1 0.5 0 0 — 0 1 0 0 sum (2.5)/answers (8) 2.5/8 = 0.31
Option 12 1 1 0 0 1 1 0.5 1 1 sum (6.5)/answers (9) 6.5/9 = 0.72
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funding agencies (eg, governmental agencies, 
private organizations, public-private partner-
ships, international and regional organiza-
tions, taxpayers of a certain region), direct re-
cipients of the funding (eg, researchers and 
research institutions), users of the research (eg, 
policy makers, industry, or the general popula-
tion of a country), and any other group with 
interest in prioritization process (eg, advocacy 
groups, journalists and media, lawyers, econo-
mists, experts in ethics, and many others). To 
ensure legitimacy and fairness of priority set-
ting decisions in health research investments, 
involvement of a wide range of stakeholders is 
recommended.
Stakeholders from the wider communi-
ty are usually not included in the process be-
cause they lack sufficient technical expertise. 
The CHNRI methodology developed a strat-
egy of involving the stakeholders in the pro-
cess regardless of their technical expertise. This 
can be done by modifying intermediate scores 
(which are entirely based on the structured in-
put from technical experts) according to the 
stakeholders’ system of values. In this way, the 
final research priority score for each research 
option will contain the input from both tech-
nical experts and the stakeholders. Although 
the stakeholders do not have enough techni-
cal expertise to score research options accord-
ing to chosen priority-setting criteria, they 
can still score the chosen criteria. This is ex-
pected to reveal how much each criterion mat-
ters to them relative to the others. In this way, 
the wider group of stakeholders may still sub-
stantially influence the final outcome of the 
process. The stakeholders can: (i) define min-
imal score (threshold) for each intermediate 
score (criterion) that needs to be achieved to 
consider any research option a funding prior-
ity; and (ii) allocate different weights to inter-
mediate scores, so that the overall score is not 
a simple arithmetic mean of the intermediate 
scores, but rather the weighted mean that re-
flects relative values assigned to each criterion 
by the stakeholders.
Thresholds will prevent investments in re-
search options that dramatically fail any of the 
criteria to which stakeholders are particular-
ly sensitive, regardless how well these research 
options were scored against other criteria. 
Weights will ensure that some intermediate 
scores, which relate to priority setting criteria 
that are seen as more important, would influ-
ence the value of the final score more than the 
others. Values for thresholds and weights can 
be obtained through a simple survey conduct-
ed among the appropriate group of represen-
tatives of the stakeholders (“larger reference 
group”). Table 3 shows an example. Further 
details are available in the article by Kapiriri et 
al (8).
Adjusting intermediate scores taking into 
account the values of stakeholders
The managers of the process need to compute 
average thresholds and weights for each crite-
rion based on the suggestions obtained from 
the survey in a larger reference group of stake-
holders. They need to check if all intermediate 
scores for all research options pass all the sug-
gested thresholds. Research options that fail to 
pass all the thresholds should be disqualified at 
this stage and not considered funding priorities.
Then, every intermediate score received by 
each research option should be multiplied by 
the average weight (amount of assigned US$) 
suggested by the larger reference group of 
stakeholders. The products represent “weight-
ed intermediate scores.” These scores will be 
used to compute an overall score (see next 
step), which will reflect both the input from 
technical experts and the stakeholders.
The actual size and composition of the 
larger reference group of stakeholders will de-
pend on the context. Small reference group of 
stakeholders is appropriate when several major 
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donors to any health research-funding organi-
zation want to influence priority setting pro-
cess. They can set very specific thresholds and 
weights for each criterion. Large and diverse 
reference group of stakeholders is more appro-
priate for priority setting for health research 
on problems of regional or global importance.
Calculating overall priority scores and 
assigning ranks
Intermediate scores for each research option 
that are based on the scores received from 
technical experts will range between 0%-
100%. At that point, the managers of the pro-
cess can simply agree that all criteria that they 
initially chose for priority setting are equally 
important (because all of them are needed to 
get from new knowledge to decrease in disease 
burden). In that case, an overall research pri-
ority score (RPS) will be a simple mean of all 
intermediate scores.
In a hypothetical example shown in Figure 
2, research option received five intermediate 
scores from technical experts: 60%, 80%, 70%, 
60% and 80%, respectively. This would mean 
that its overall RPS can be computed as fol-
lows:
RPS = (60% + 80% + 70% + 60% + 80%)/5 = 70%
However, if stakeholders were also in-
volved and a survey was undertaken among 
them to include their values in the process, it 
could provide hypothetical average thresholds 
for the five criteria (50%, 50%, 40%, 20%, and 
60%, respectively), and also hypothetical aver-
age weights (US $15, $15, $15, $30, and $25, 
respectively). In this case, the initial check will 
establish that all thresholds have been passed 
and that the research option from the example 
below remains in the contest for the funding. 
Then, the weights are applied as shown below 
and the overall RPS is corrected to 69.5%. Af-
ter computing weighted RPS for all research 
Table 3. An example of a simple questionnaire that can be used to survey different stakeholders and obtain their input into the Child 
Health and Nutrition Research Initiative process
Below are the criteria that can be used to set priorities in health research investments. - In the “threshold” column, please enter the minimum acceptable 
score (on a scale 0-100) for each criterion that should be achieved by proposed health research to receive funding support.
- In the “weight” column, please distribute a total of US $100 to the 5 proposed criteria to reflect how much does each criterion matter to you.
Criterion Threshold Weight
Answerability (likelihood that the research will indeed reach its proposed endpoints)
Effectiveness (likelihood that the results of the research will have effect against the disease)
Deliverability (likelihood that the results of the research will be delivered to those who need them)
Maximum impact (likelihood that the research can influence a substantial share of disease cases)
Equity (likelihood that the results of the research will improve health inequities in the population)
Figure 2. Calculation of overall research priority score (RPS) based on 5 hypothetically chosen priority setting criteria (C1-C5); values W1-W5 
are factors by which each criterion is weighted (computed as average weights for each criterion obtained from the survey among stakeholders (in 
dark gray), achieved intermediate scores (IS1-IS5) for each research option (in light gray); the required thresholds for intermediate scores for each 
criterion (computed as average thresholds for each criterion obtained from the survey among stakeholders). The final research priority score for 
each proposed research option is defined as their weighted average: [W1 × IS1 + W2 × IS2 + … + Wn × ISn/(W1+W2+…+Wn). In the hypothetical case 
below, the overall RPS should equal (15 × 0.6 + 15 × 0.8 + 15 × 0.7 + 30 × 0.6 + 25 × 0.8)/100 = 69.5%.
Croat Med J 2008;49:720-733
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options that passed all the thresholds, the op-
tions can be ranked by priority according to 
their achieved RPS.
Performing an analysis of agreement 
between scorers
Scoring performed by technical experts is both 
independent and transparent to process man-
agers. Therefore, the CHNRI methodology of-
fers the potential to expose the points of the 
greatest agreement and the greatest controver-
sy among the experts. Identification of these 
points should allow more focused discussion 
on the priorities after the completion of the 
process. In this way, in addition to the infor-
mation on how each research option complies 
with the chosen priority-setting criteria, inves-
tors and policy makers are informed about the 
amount of agreement between the experts on 
each research option.
The level of agreement can be assessed 
for each specific research option using agree-
ment statistics (κ). This calculation becomes 
extremely complicated when the number of 
scorers exceeds 2 and the number of rating 
categories exceeds 2. We suggest that all ob-
servations where the expert reviewer chose 
0.5 (“knowledgeable, but the answer is inde-
terminate”) should first be recoded as miss-
ing values, restricting the number of rating 
categories to 2 and making the calculation of 
the κ statistics more meaningful. The decision 
to choose 0.5 is nearly equivalent to choos-
ing to leave the answer field blank, since in 
both situations the expert reviewer is reveal-
ing that his or her answer to the question is 
unknown.
Kappa value should be computed for each 
research question as a measure of the level of 
agreement among the scorers. When the num-
ber of scorers is variable across subjects, statis-
tical significance testing cannot be performed. 
Interpreting κ statistics is arbitrary, and the 
greater the κ, the greater the level of agree-
ment. Further details on calculation of κ can 
be found elsewhere (9).
Linking computed research priority scores 
with investment decisions
There are two main scenarios in which pro-
cess managers will link research priority scores 
with investment decisions. The first one is de-
signing an investment strategy before actual 
investments are made. The second one is mod-
ifying an already existing investment portfolio 
to reduce risk and/or increase returns on in-
vestments.
In the first scenario, a donor agency or 
organization will conduct an informative 
CHNRI process to define its priorities be-
fore it commits to funding and launching of 
the calls for grant proposals. In this case, we 
argue that investing in health research is fun-
damentally not much different than investing 
in stocks of different companies on the stock 
market. Rather than making investment de-
cisions by comparing companies, investors in 
health research will be choosing between many 
groups of health researchers and their research 
grant proposals. Seen in this way, investors in 
health research should learn from the vast ex-
perience and literature on investment in finan-
cial markets (10).
Among many analogies, “high risk” health 
research investment is the one with very uncer-
tain (or unlikely) answerability, transferabili-
ty (usefulness) or potential impact on disease 
burden reduction. “High profit” health re-
search investment is the one offering very high 
reduction in disease burden if successful. There 
will be investments in health research that of-
fer lower “profits,” but also at lower “risks” 
(such as research on improvement of existing 
interventions); and also “high-risk high-prof-
it” investment options (eg, research to develop 
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new and non-existent vaccines against malaria 
or AIDS).
There is always a risk and a potential profit 
associated with any investment. The risk pref-
erence of the investors will therefore represent 
an important determinant of their investment 
strategy. For a rational investor, the probability 
of success always needs to be balanced against 
the probability of failure. The preferences of 
both those who tend to seek or to avoid risk 
have costs in terms of reduced expected prof-
its, which is easy to demonstrate with standard 
expected utility theory (11). While this theory 
does not normatively qualify some preferenc-
es as better than others, a common suggestion 
is that rational actors who are sufficiently large 
for risk pooling should base investment deci-
sions on preferences that are risk-neutral, as 
this strategy leads to highest profits in the long 
run (11,12). This implies that an unbalanced 
investment portfolio, in which large major-
ity of investments are in “low-risk low-profit” 
health research options or in “high-risk high-
profit” options, is neither rational nor respon-
sible. However, because there is very little ac-
countability for poor investment decisions in 
health research and their evaluation in terms 
of benefits for the society, we are witnessing 
an increasing trend of global research portfolio 
becoming unbalanced and favoring “high-risk 
high-profit” health research options (12).
In an alternative scenario, international 
funding agency or national government has al-
ready been funding health research for sever-
al years and would like to improve the mix of 
supported research options. In this case, a clas-
sical “program budgeting and marginal analysis 
would be appropriate:” (i) identifying funding 
cut-off points and RPSs for funded research 
options; (ii) comparing research options that 
have no allocated funding to existing funding 
programs; (iii) assessing relative value of each 
priority using the same criteria; (iv) releasing 
resources from existing programs to support 
additional new priority research areas (13). All 
decisions that need to be made within this sce-
nario are based on: (i) defining RPS and cost 
of each research option, either already sup-
ported or proposed as an alternative; (ii) max-
imizing the sum of RPS values of supported 
research options within a given fixed budget; 
(iii) if the sum of RPS scores within an exist-
ing program is lower than the sum of the al-
ternative, resources should be shifted from the 
existing into the new research options.
Feedback and revision
CHNRI methodology is a process which does 
not end with definition of health research pri-
orities and allocation of funding. The invest-
ments are expected to lead to changes in the 
context over time in terms of disease burden. 
Other components of the contexts may also 
change substantially, from stakeholders’ sys-
tem of values to limits in space or risk man-
agement preferences. All these changes can be 
accounted for by: (i) adding further research 
options to the list; (ii) adding additional cri-
teria; (ii) re-scoring all research options in the 
redefined context; and (iii) revising thresholds 
and weights placed on intermediate scores. In 
this way, the research investment portfolio 
will continuously be adjusted to the context 
and aim to reduce the existing disease burden 
most cost-effectively and in an equitable way.
Conclusion
Some of the possible advantages of CHNRI’s 
research priority-setting methodology in-
clude: (i) transparent presentation of the 
context and criteria in the priority setting 
process; (ii) management of the process by 
investors themselves over its entire duration; 
(iii) structured way of scoring, which should 
limit specific interests or personal biases; 
(iv) · involvement of non-technical stakehold-
Croat Med J 2008;49:720-733
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ers in priority setting; (v) the flexibility of the 
process provided by adding or subtracting 
the criteria; (vi) potential to revise weights 
and thresholds based on the changes in the 
context; (vii) · simple presentation of the 
strengths and weaknesses of each competing 
research option; (viii) possibility to rank re-
search options according to each individual 
criterion; (ix) a simple quantitative outcome 
that is easy to present, justify, and explain to 
policy-makers; (x) exposure of the points of 
the greatest agreement and controversy. Al-
though the proposed guidelines are based 
on wide consultations and extensive review 
and assessment of previous approaches, the 
CHNRI method will eventually benefit from 
independent validation in various settings in 
the future. It will be even more challenging to 
define the real impact of the process on shift-
ing global research priorities. That is the ul-
timate goal of CHNRI method and the one 
that will leverage support for health research 
to make more impact on the disease burden 
in the real world.
Still, the methodology is not free of sev-
eral possible biases. Although the advantages 
mentioned above represent a serious attempt 
to deal with many issues inherent to a highly 
complex process of research investment prior-
ity setting, there are still concerns over the va-
lidity of the CHNRI approach and related bi-
ases. One of them is related to the fact many 
possible good ideas (“research investment op-
tions”) may not have been included in the ini-
tial list of research options that was scored by 
the experts, and to the potential bias toward 
items that get the greatest press. The spectrum 
of research investment options listed initially 
in this exercise was derived through a system-
atic process, but it is not endless and it cannot 
ever cover every single research idea. Specific 
research methodologies (ie, randomized clin-
ical trials) are not mentioned because the re-
search questions listed in that exercise are un-
likely to be answered by a single well-defined 
study. Therefore, the CHNRI process aims to 
achieve reasonable coverage of the spectrum of 
possible ideas.
Another concern over the CHNRI process 
is that its end product represents a possibly 
biased opinion of a very limited group of in-
volved people. In theory, a chosen group of ex-
perts can have biased views in comparison with 
any other potential groups of experts. Howev-
er, the number of people who possess enough 
experience, expertise, and knowledge on the is-
sue to be able to judge a very diverse spectrum 
of research questions is rather limited. If one 
thinks of this “pool of technical experts” as 
the whole population that could theoretically 
be used to solicit expert opinion on the ques-
tions that need to be asked, we then propose 
selection of a “sample” from that population, 
based on their track record. The larger and the 
more diverse this sample is, the less likely it is 
that there would be considerable differences in 
the composition of the initial list of questions 
(or results of the scoring process) if some other 
group of experts had been selected.
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